COHANCE

Cohance Lifesciences Share Price

₹995.10 +1.6 (0.16%)

18 Jun, 2025 08:11

SIP TrendupStart SIP in COHANCE

Start SIP

Performance

  • Low
  • ₹982
  • High
  • ₹1,009
  • 52 Week Low
  • ₹696
  • 52 Week High
  • ₹1,360
  • Open Price₹985
  • Previous Close₹994
  • Volume115,331

Investment Returns

  • Over 1 Month -7.79%
  • Over 3 Month -12.34%
  • Over 6 Month -21.38%
  • Over 1 Year + 38.37%
SIP Lightning

Smart Investing Starts Here Start SIP with Cohance Lifesciences for Steady Growth!

Invest Now

Cohance Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 94.6
  • PEG Ratio
  • -8.8
  • Market Cap Cr
  • 25,332
  • P/B Ratio
  • 12.8
  • Average True Range
  • 39.24
  • EPS
  • 7
  • Dividend Yield
  • 0
  • MACD Signal
  • -23.35
  • RSI
  • 36.28
  • MFI
  • 26.91

Cohance Lifesciences Financials

Cohance Lifesciences Technicals

EMA & SMA

Current Price
₹995.10
+ 1.6 (0.16%)
pointer
  • stock-down_img
  • Bearish Moving Average 16
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,036.36
  • 50 Day
  • ₹1,074.38
  • 100 Day
  • ₹1,098.55
  • 200 Day
  • ₹1,074.17

Resistance and Support

995.3 Pivot Speed
  • R3 1,034.80
  • R2 1,021.70
  • R1 1,008.40
  • S1 982.00
  • S2 968.90
  • S3 955.60

What's your outlook on Cohance Lifesciences?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Suven Pharmaceuticals Ltd. is a leading pharmaceutical company specializing in contract development and manufacturing services (CDMO). It focuses on producing intermediates and active pharmaceutical ingredients (APIs), serving global pharmaceutical companies with innovative and high-quality solutions.

Cohance Lifesciences Ltd has an operating revenue of Rs. 1,197.58 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 29% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 26% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 51 which is a POOR score indicating inconsistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Cohance Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-28 Audited Results
2025-02-12 Quarterly Results
2024-11-12 Quarterly Results
2024-08-09 Quarterly Results
2024-05-30 Audited Results (Revised) per share(100%)Interim Dividend
Date Purpose Remarks
2022-09-12 INTERIM Rs.1.00 per share(100%)Interim Dividend
2022-09-12 SPECIAL Rs.5.00 per share(500%)Special Dividend
2022-05-17 INTERIM Re.1.00 per shaer (100%) Second Interim Dividend
2022-05-17 SPECIAL Rs.1.00 per share(100%)Special Dividend
2022-02-16 INTERIM Rs.1.00 per share(100%)Interim Dividend
View More

Cohance Lifesciences F&O

Cohance Lifesciences Shareholding Pattern

66.41%
8.65%
2.17%
7.38%
0%
6.63%
8.76%

About Cohance Lifesciences

  • NSE Symbol
  • COHANCE
  • BSE Symbol
  • 543064
  • Managing Director
  • Dr. V Prasada Raju
  • ISIN
  • INE03QK01018

Similar Stocks to Cohance Lifesciences

Cohance Lifesciences FAQs

Cohance Lifesciences share price is ₹995 As on 18 June, 2025 | 07:57

The Market Cap of Cohance Lifesciences is ₹25331.8 Cr As on 18 June, 2025 | 07:57

The P/E ratio of Cohance Lifesciences is 94.6 As on 18 June, 2025 | 07:57

The PB ratio of Cohance Lifesciences is 12.8 As on 18 June, 2025 | 07:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23